Search

1284 Result(s)
Sort by

Women in STEM 2022

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Women in STEM: Passion for science

Women in STEM: Passion for science

Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
International Women's Day

International Women's Day

We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
Heart Failure in Women

Heart Failure in Women

Experts discuss disparities in heart failure care and management for women
Celebrating Women in Technology

Celebrating Women in Technology

We want to elevate women in technology: empower them, affirm their potential and enable them to soar to new heights
Women in the workplace: Inspiring inclusion

Women in the workplace: Inspiring inclusion

On International Women’s Day, we address the critical role of women in our society and ensure their voice is heard at all levels of our organization.
3 tips for anyone interested in a STEM career

3 tips for anyone interested in a STEM career

What does it take to pursue a career in science? We asked Dr. Joanne Maki, a Boehringer Ingelheim veterinarian and scientist based in Athens, Ga.
Systemic sclerosis physician video

Systemic sclerosis physician video

In this video Professor Chris Denton (Consultant Rheumatologist) discusses his experience diagnosing systemic sclerosis, also known as scleroderma
Management Systems

Management Systems

Suppliers shall use management systems to support continuous improvement and compliance with the Supplier Code of Conduct.
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Our Partners Harvard

Our Partners Harvard

Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD